Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Follow along on our guide to Multiple Myeloma, a cancer of the bone marrow's infection-fighting plasma cells. As cancerous ...

From uncertainty to hope for the future, they offer advice on getting through some of the toughest years of their lives ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Multiple Genetic Abnormalities Lead to Poor Prognosis Around 5900 people are diagnosed with myeloma each year ... chemotherapy, and stem cell transplants. More than half of patients survive ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly ... in maintenance therapies after autologous stem cell transplantation (ASCT) and following frontline ...

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...

with bortezomib (Velcade), lenalidomide (Revlimid), and limited dexamethasone was safe and effective for older multiple myeloma patients ineligible for autologous hematopoietic stem cell ...

Superiority of melphalan–prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma.